Two commercial-scale drug product manufacturing facilities currently under construction are expected to become operational later this year and early next year, respectively. STA Pharmaceutical, after this merger, will provide fully integrated small molecule Active Pharmaceutical Ingredient (API) and drug product solutions to global clients, resulting in a seamless Chemistry, Manufacturing and Control (CMC) working process. The merger enables STA to advance New Chemical Entities from preclinical stage to New Drug Application (NDA) and to market faster and more efficiently for pharma and biotech customers.